Non-small-cell lung carcinomas with activating mutations in epidermal growth factor receptor (EGFR) frequently respond to treatment with tyrosine kinase inhibitors targeting EGFR, but the responses are not durable, as tumors acquire resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.